Delvens published a new research publication on "Pendred Syndrome (PS) Market Insights, to 2030" with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Pendred Syndrome (PS) market was mainly driven by the increasing R&D spending across the world, The global Pendred Syndrome (PS) market size was estimated at USD 2.82 billion in 2023 and is projected to reach USD 3.83 billion in 2030 at a CAGR of 4.5% during the forecast period 2023-2030.

Get Free Sample Report: https://www.delvens.com/get-free-sample/pendred-syndrome-ps-market

Pendred syndrome, often abbreviated to PS, is a rare genetic disorder characterized by a combination of sensorineural hearing loss and thyroid dysfunction. It is named after British physician Vaughan Pendred, who first described the syndrome in the early 20th century.

Pendred syndrome is caused by mutations in the SLC26A4 gene, also known as the pendrin gene. This gene codes for a protein called pendrin, which plays a critical role in the transport of ions (charged particles) through the cell membranes of the cochlea and thyroid gland.

The global pendred syndrome market is growing steadily due to the prevalence of pendred syndrome and rising healthcare costs. Growing R&D activity is significantly driving the global flexion syndrome market. Strategic initiatives by major market players are one of the reasons for the rapid growth of the market. Market participants are expanding their product offerings to gain a competitive advantage.

North America to Dominate the Pendred Syndrome (PS) Market:

·        North America is estimated to account for the largest market share during the forecast period due to rising healthcare costs, increased R & D, and trending technological advancements.

·        Moreover, Moreover, growing focus of major key players on further R&D will further propel the market’s growth rate in this region.

The prominent players in the Pendred Syndrome (PS) market are:

·        Advanced Bionics AG

·        Amplifon

·        Audina Hearing Instruments, Inc.

·        Cochlear Ltd

·        Demant A/S

·        ElkonPvt Ltd

·        GAES

·        GN Store Nord A/S

·        MED-EL Medical Electronics

·        Nobel pharma Co.,Ltd

·        Nurotron Biotechnology Co. Ltd

·        Rion Co. Ltd

·        Sensorion

·        Sonova

·        Starkey and More

For More Inquiry Contact us: https://www.delvens.com/Inquire-before-buying/pendred-syndrome-ps-market

Recent Developments of Pendred Syndrome (PS) Market:

Biotechnology Companies: Biotechnology companies may focus on advancing gene therapy approaches for Pendred Syndrome. This includes research into gene editing technologies, viral vectors, and delivery mechanisms to correct or replace the faulty SLC26A4 gene in affected individuals.

Research Institutions and Academia: Academic institutions and research organizations play a significant role in studying rare genetic disorders like Pendred Syndrome. Their contributions may include conducting studies to understand the underlying mechanisms of the disease, exploring potential therapeutic targets, and collaborating with industry partners to translate research findings into clinical applications.

Key Findings

·        The Treatment segment is further fragmented into Cochlear Implant, Hearing Aids, and Radioactive Iodine. The Cochlear Implant segment is expected to account for a larger market size during the forecast period. Cochlear implants are electronic devices that are surgically implanted into the inner ear to provide a sense of sound for individuals with severe to profound hearing loss. In Pendred Syndrome, where sensorineural hearing loss is a common feature, cochlear implants can be considered for those who do not significantly benefit from conventional hearing aids.

·        The diagnosis segment is further bifurcated into Genetic Testing, Perchlorate Washout Test, and Others. The Genetic Testing is the largest market during the forecast period. Genetic testing is a crucial tool in diagnosing Pendred Syndrome. This involves analyzing the DNA of an individual to identify mutations in the SLC26A4 gene, which is associated with the syndrome. Genetic testing can confirm the presence of mutations that lead to abnormal functioning of the pendrin protein. Identifying these mutations can help establish a definitive diagnosis of Pendred Syndrome.

·        The End- Users segment is further bifurcated into Hospitals, Homecare, Specialty Clinics, Otolaryngologist, and Others. The Hospitals is the largest market during the forecast period. Hospital-based otolaryngologists (ear, nose, and throat specialists) can assess the severity of hearing loss, conduct inner ear imaging, and provide guidance on treatment options, including hearing aids and cochlear implants. Hospitals also facilitate communication and collaboration between different medical specialists involved in the care of individuals with Pendred Syndrome.

·        The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period owing to the rising healthcare costs, increased R & D, and trending technological advancements.

Access Full Report: https://www.delvens.com/report/pendred-syndrome-ps-market

In addition to the market data for the Pendred Syndrome (PS) Market, Delvens offers client-centric reports customized according to the company’s specific demand and requirements.

Frequently Asked Questions

·        What are the years considered to study Pendred Syndrome (PS) Market?

·        What is the compound annual growth rate (CAGR) of the Pendred Syndrome (PS) Market?

·        Which region holds the largest market share in Pendred Syndrome (PS) Market?

·        Which region is the fastest growing in Pendred Syndrome (PS) Market?

·        Who are the major players in Pendred Syndrome (PS) Market?

More Reports From Delvens:

Antacids market

Multiple Sclerosis (MS) market

About Us:

Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.

Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.

Contact us:

UNIT NO. 2126, TOWER B,

21ST FLOOR ALPHATHUM

SECTOR 90 NOIDA 201305, IN

+44-20-3290-6466

+1 214-377-1144